20-hydroxyecdysoneWhat was measured
Measured, with no finding
177 endpoints
Show what was measuredHide what was measured
triglycerides
no effect, p = 0.62
triglycerides (p = 0.62)
PMID 18500969 · one of two readings recorded this
uric acid
no effect, p = 0.57
uric acid (p = 0.57)
PMID 18500969 · one of two readings recorded this
hemoglobin
no effect, p = 0.74
hemoglobin (p = 0.74)
PMID 18500969 · one of two readings recorded this
GGT
no effect, p = 0.86
GGT (p = 0.86)
PMID 18500969 · one of two readings recorded this
MCH
no effect, p = 0.2
MCH (p = 0.20)
PMID 18500969 · one of two readings recorded this
AST
no effect, p = 0.16
AST (p = 0.16)
PMID 18500969 · one of two readings recorded this
1-RM bench press, training effect
increases, p = 0.0001
1-RM bench press (pre: 94.94 ± 22.8 to post: 100.84 ± 20.54 kg, p =< 0.0001)
PMID 18500969 · one of two readings recorded this
1-RM leg press, training effect
increases, p = 0.0001
1-RM leg press (311 ± 76 to 341 ± 82 kg, p =< 0.0001)
PMID 18500969 · one of two readings recorded this
ALT
no effect, p = 0.56
ALT (p = 0.56)
PMID 18500969 · one of two readings recorded this
basophils change
modulates, p = 0.04
basophils (7.5 ± 7.6; 7.6 ± 25.1; 6.57 ± 16.1; 4.4 ± 7.8 k/μL, p = 0.04)
PMID 18500969 · one of two readings recorded this
bench press 1-RM change
no effect, p = 0.29
bench press 1-RM (6.2 ± 7; 2.5 ± 5; 7.2 ± 10; 7.7 ± 6 kg, p = 0.29)
PMID 18500969 · one of two readings recorded this
bench press lifting volume change
modulates, p = 0.008
Bench press lifting volume was significantly greater in the M group (105 ± 120; 102 ± 200; 124 ± 174; 25 ± 176 kg, p = 0.008)
PMID 18500969 · one of two readings recorded this
BUN, E arm, T1 to T3
no effect, p = 0.97
E | 16.2 ± 3.1 | 15 ± 2.7 | 14.7 ± 3.3 | GxT |.970
PMID 18500969 · one of two readings recorded this
CK, E arm, T1 to T3
no effect, p = 0.091
E | 172 ± 83 | 228 ± 133 | 159 ± 64 | GxT |.091
PMID 18500969 · one of two readings recorded this
cortisol change
no effect, p = 0.57
cortisol (2.68 ± 2.46, 1.11 ± 6.3, 1.93 ± 5.57, 1.66 ± 10.54 μg/dl, p = 0.57)
PMID 18500969 · one of two readings recorded this
cortisol, E arm, T1 to T3
no effect, p = 0.571
E | 17.1 ± 4.5 | 15.6 ± 5.3 | 15.1 ± 5.8 | GxT |.571
PMID 18500969 · one of two readings recorded this
creatinine, E arm, T1 to T3
no effect, p = 0.537
E | 1.2 ±.13 | 1.1 ±.16 | 1.2 ±.13 | GxT |.537
PMID 18500969 · one of two readings recorded this
DEXA fat free mass change
no effect, p = 0.4
mean fat free mass (P 0.94 ± 1.5; M 0.29 ± 1.4; E -0.04 ± 1.3; CSP3 0.64 ± 1.4 kg, p = 0.40)
PMID 18500969 · one of two readings recorded this
DEXA fat free mass, fat mass, 1-RM bench press and leg press, Wingate power, serum cortisol and testosterone; arm E dosed 100 mg/day Polypodium vulgare/Suma root standardized for 30 mg 20-hydroxyecdysone vs dextrose placebo, 8 weeks with resistance training
no effect, DEXA fat free mass change among P, M, E and CSP3 groups, p = 0.40, p = 0.4
Not recorded as a finding: the only supporting sentence runs past the quote limit
However, no statistically significant differences were observed among the P, M, E, and CSP3 groups, respectively, in mean fat free mass (P 0.94 ± 1.5; M 0.29 ± 1.4; E -0.04 ± 1.3; CSP3 0.64 ± 1.4 kg, p = 0.40), fat mass (P0.69 ± 1.1; M 0.32 ± 1.6; E 0.69 ± 1.1; CSP3 -0.36 ± 0.7 kg, p = 0.17), percent body fat (P 0.59 ± 1.7; M 0.08 ± 1.7; E 0.70 ± 1.0; CSP3 -0.46 ± 0.8%, p = 0.18), or total body water (P 0.39 ± 3.3, M 0.16 ± 2.9, E 1.7 ± 2.5, CSP3 0.31 ± 2.4 L, p = 0.61).
PMID 18500969 · one of two readings recorded this
DEXA fat free mass, fat mass and percent body fat, 1-RM bench press and leg press, Wingate power, serum total testosterone and cortisol, over 8 weeks of resistance training; the Results name the arm only as E, and the only Methods sentence defining E (100 mg/day of Polypodium Vulare/Suma root standardized for 30 mg of 20-hydroxyecdysone) is over 40 words of prose because its brackets carry no digits
no effect, change in fat free mass, E -0.04 +/- 1.3 kg against P 0.94 +/- 1.5 kg among four groups, p = 0.4
Not recorded as a finding: the only supporting sentence runs past the quote limit
However, no statistically significant differences were observed among the P, M, E, and CSP3 groups, respectively, in mean fat free mass (P 0.94 ± 1.5; M 0.29 ± 1.4; E -0.04 ± 1.3; CSP3 0.64 ± 1.4 kg, p = 0.40), fat mass (P0.69 ± 1.1; M 0.32 ± 1.6; E 0.69 ± 1.1; CSP3 -0.36 ± 0.7 kg, p = 0.17), percent body fat (P 0.59 ± 1.7; M 0.08 ± 1.7; E 0.70 ± 1.0; CSP3 -0.46 ± 0.8%, p = 0.18), or total body water (P 0.39 ± 3.3, M 0.16 ± 2.9, E 1.7 ± 2.5, CSP3 0.31 ± 2.4 L, p = 0.61).
PMID 18500969 · one of two readings recorded this
DEXA fat free mass, training effect
increases, p = 0.03
Training resulted in a statistically significant increase (p = 0.03) in DEXA fat free mass
PMID 18500969 · one of two readings recorded this
dietary carbohydrate intake, E arm, T1 to T3
no effect, p = 0.491
E | 4.7 ± 1 | 3.8 ±.83 | 3.9 ± 1.2 | GxT |.491
PMID 18500969 · one of two readings recorded this
dietary fat intake, E arm, T1 to T3
no effect, p = 0.67
E | 1.5 ±.8 | 1.2 ±.29 | 1.2 ±.39 | GxT |.670
PMID 18500969 · one of two readings recorded this
dietary protein intake, E arm, T1 to T3
no effect, p = 0.815
E | 1.7 ±.34 | 1.7 ±.34 | 1.4 ±.44 | GxT |.815
PMID 18500969 · one of two readings recorded this
dietary total calories, E arm, T1 to T3
no effect, p = 0.826
E | 40 ± 12 | 31 ± 6 | 32 ± 7 | GxT |.826
PMID 18500969 · one of two readings recorded this
eosinophils
no effect, p = 0.28
eosinophils (p = 0.28)
PMID 18500969 · one of two readings recorded this
fat mass change
no effect, p = 0.17
fat mass (P0.69 ± 1.1; M 0.32 ± 1.6; E 0.69 ± 1.1; CSP3 -0.36 ± 0.7 kg, p = 0.17)
PMID 18500969 · one of two readings recorded this
free testosterone change
no effect, p = 0.25
free testosterone (4.39 ± 10.4, 5.54 ± 6.85, 1.39 ± 11.84, 1.77 ± 8.62 pg/ml, p = 0.25)
PMID 18500969 · one of two readings recorded this
hematocrit
no effect, p = 0.61
hematocrit (p = 0.61)
PMID 18500969 · one of two readings recorded this
LDH, E arm, T1 to T3
no effect, p = 0.359
E | 126 ± 23 | 124 ± 12 | 124 ± 14 | GxT |.359
PMID 18500969 · one of two readings recorded this
leg press 1-RM change
no effect, p = 0.63
leg press 1-RM (20.6 ± 33; 37.0 ± 39; 38.9 ± 45; 29.3 ± 36 kg, p = 0.63)
PMID 18500969 · one of two readings recorded this
leg press lifting volume change
modulates, p = 0.04
leg press lifting volume was lower in the M group (97 6 ± 1,213; -799 ± 1,718; 1,259 ± 1,153; 978 ± 2,328 kg, p = 0.04)
PMID 18500969 · one of two readings recorded this
lymphocytes
no effect, p = 0.44
lymphocytes (p = 0.44)
PMID 18500969 · one of two readings recorded this
MCHC
no effect, p = 0.29
MCHC (p = 0.29)
PMID 18500969 · one of two readings recorded this
MCV
no effect, p = 0.68
MCV (p = 0.68)
PMID 18500969 · one of two readings recorded this
monocytes
no effect, p = 0.66
monocytes (p = 0.66)
PMID 18500969 · one of two readings recorded this
neutrophils change
modulates, p = 0.04
significant changes were seen in neutrophils (2.05 ± 9.9; 4.4 ± 10.1; 4.3 ± 5.5, 5.8 ± 7.4 k/μL:, p = 0.04)
PMID 18500969 · one of two readings recorded this
percent body fat change
no effect, p = 0.18
percent body fat (P 0.59 ± 1.7; M 0.08 ± 1.7; E 0.70 ± 1.0; CSP3 -0.46 ± 0.8%, p = 0.18)
PMID 18500969 · one of two readings recorded this
red blood cell counts
no effect, p = 0.39
red blood cell counts (p = 0.39)
PMID 18500969 · one of two readings recorded this
serum protein
no effect, p = 0.65
serum protein (p = 0.65)
PMID 18500969 · one of two readings recorded this
total body water change
no effect, p = 0.61
total body water (P 0.39 ± 3.3, M 0.16 ± 2.9, E 1.7 ± 2.5, CSP3 0.31 ± 2.4 L, p = 0.61)
PMID 18500969 · one of two readings recorded this
total cholesterol
no effect, p = 0.48
total cholesterol (p = 0.48)
PMID 18500969 · one of two readings recorded this
total lifting volume, lower body
no effect, p = 0.94
lower body (P 398,976 ± 77,553; M 408,966 ± 113,746; E 448,371 ± 189,738; CSP3 422,163 ± 167,259 kg; p = 0.94)
PMID 18500969 · one of two readings recorded this
total lifting volume, upper body
no effect, p = 0.83
total lifting volume during the training period for upper body (P 322,984 ± 106,936; M 304,987 ± 51,955; E 275,744 ± 72,658; CSP3 313,308 ± 112,077 kg; p = 0.83)
PMID 18500969 · one of two readings recorded this
total testosterone change
no effect, p = 0.67
total testosterone (0.21 ± 0.83, 0.26 ± 1, 0.02 ± 1.21, 0.10 ± 0.93 ng/ml, p = 0.67)
PMID 18500969 · one of two readings recorded this
total testosterone to cortisol ratio change
no effect, p = 0.43
total testosterone to cortisol ratio (0.05 ± 0.09, 0.02 ± 0.16, 0.06 ± 0.17, 0.02 ± 0.16, p = 0.43)
PMID 18500969 · one of two readings recorded this
WBC
no effect, p = 0.076
WBC (p = 0.076)
PMID 18500969 · one of two readings recorded this
Wingate mean power change
no effect, p = 0.55
Wingate mean power (20 ± 83; -13 ± 88; -18 ± 76; -15 ± 52 W, p = 0.55)
PMID 18500969 · one of two readings recorded this
Wingate peak power change
no effect, p = 0.82
Wingate peak power (82 ± 248; 30 ± 139; 28 ± 151; 17 ± 171 W, p = 0.82)
PMID 18500969 · one of two readings recorded this
Wingate total work change
no effect, p = 0.29
Wingate total work (582 ± 2,564; -216 ± 2,716; -420 ± 2,291; -528 ± 1,514 J, p = 0.29)
PMID 18500969 · one of two readings recorded this
Elimination of G. lamblia after therapy
increases
After therapy, elimination of G. lamblia was observed in 100.0% of the athletes included in the 20-hydroxyecdysone group
PMID 36617399 · one of two readings recorded this
elimination of Giardia lamblia after therapy in athletes with giardiosis, parasitological analysis
100.0% elimination in the 20-hydroxyecdysone group
Not recorded as a finding: this platform holds no node for the endpoint
After therapy, elimination of G. lamblia was observed in 100.0% of the athletes included in the 20-hydroxyecdysone group.
PMID 36617399 · one of two readings recorded this
elimination of Giardia lamblia after therapy, parasitological analysis
increases, G. lamblia eliminated in 100.0% of athletes in the 20-hydroxyecdysone group
Not recorded as a finding: this platform holds no node for the endpoint
After therapy, elimination of G. lamblia was observed in 100.0% of the athletes included in the 20-hydroxyecdysone group.
PMID 36617399 · one of two readings recorded this
G. lamblia resistance to metronidazole
G. lamblia was resistant to metronidazole in 4.0% of athletes included in the metronidazole group
PMID 36617399 · one of two readings recorded this
20E plasma Cmax, fed versus fasted
increases
20E plasma Cmax and AUCs were slightly higher in fed than in fasted conditions at 700 mg (+24% for Cmax and +20%–22% for AUCs
PMID 37057316 · one of two readings recorded this
aldosterone, change from baseline at D14
no effect, p = 0.219
Aldosterone (pg/mL) | 1.767 (−24.00 + 21.60) | 3.375 (−31.30 + 36.40) | 5.486 (n = 7) (−11.70 + 43.10) | −11.200 (−42.80 + 24.10) | 0.219 (ns) | All: 0.736 (ns) 350 bid: 0.871(ns) | 0.01 0.01
PMID 37057316 · one of two readings recorded this
CK-MB, change from baseline at D14
no effect, p = 0.368
CK MB (g/L) | −0.192 (−0.36 + 0.10) | −0.130 (−0.66 + 0.35) | −0.310 (n = 7) (−0.92 + 0.15) | −0.428 (−0.95 + 0.14) | 0.368 (ns) | All: 0.027 (s) 350 mg bid: 0.008 (s) | 0.21 0.79 *
PMID 37057316 · one of two readings recorded this
CK-MB dose effect at Day 14, all healthy volunteers
decreases, p = 0.043
CK‐MB levels from all healthy volunteers show a dose effect on Day 14 (P = 0.043; Kruskal–Wallis test)
PMID 37057316 · one of two readings recorded this
CRP, change from baseline at D14
unclear
CRP (mg/L) | 0.00 (0.0 0.0) | 0.16 (0.0 + 1.3) | 0.00 (n = 7) (0.0 0.0) | −3.11 (−23.6 0.0) | nd | nd | nd
PMID 37057316 · one of two readings recorded this
hsCRP, change from baseline at D14
unclear
hsCRP (mg/L) | 0.807 (−0.64 + 3.45) | 0.024 (−1.32 + 1.53) | −0.466 (n = 7) (−3.30 + 0.59) | −0.018 (n = 6) (−0.33 + 0.32) | nd | nd | nd
PMID 37057316 · one of two readings recorded this
HSP72, change from baseline at D14
unclear
HSP72 (ng/mL) | −0.1600 (−3.70 0.0000) | 0.18375 (−0.0500 + 1.5200) | 0.06571 (n = 7) (0.0000 + 0.4600) | −0.0940 (−1.2000 + 0.6489) | nd | nd | nd
PMID 37057316 · one of two readings recorded this
IL-6, change from baseline at D14
no effect
IL‐6 (pg/mL) | 0.152 (−1.44 + 3.05) | −1.477 (n = 6) (−8.28 + 3.71) | 0.160 (n = 7) (0.00 + 1.12) | 0.4 6 (−2.52 + 3.20) | nd | nd | nd
PMID 37057316 · one of two readings recorded this
myoglobin, change from baseline at D14
no effect, p = 0.244
Myoglobin (ng/mL) | −3.70 (−18.3 + 12.7) | −2.71 (−21.5 + 9.1) | −8.46 (n = 7) (−25.1 + 4.6) | −7.43 (−15.3–3.3) | 0.244 (ns) | All: 0.272 (ns) 350 mg bid: 0.012 (s) | 0.06 0.75 *
PMID 37057316 · one of two readings recorded this
myostatin, change from baseline at D14
increases, p = 0.032
Myostatin (pg/mL) | −453.5 (−797–29) | 100.3 (−410 + 831) | 146.4 (n = 7) (−574 + 1048) | 253.4 (−590 + 876) | 0.032 (s) | All: 0.954 (ns) 350 mg bid: 0.906 (ns) | 0.0 0.0
PMID 37057316 · one of two readings recorded this
PIIINP, change from baseline at D14
no effect, p = 0.359
PIIINP (μg/mL) | −0.13 (−1.95 + 0.65) | 0.230 (−1.52 + 1.11) | 0.247 (n = 7) (−0.91 + 0.93) | 0.614 (+0.10 + 1.34) | 0.359 (ns) | All: 0.944 (ns) 350 bid: 0.484 (ns) | 0.0 0.1
PMID 37057316 · one of two readings recorded this
plasma 20E pharmacokinetics (Cmax, AUC, half-life, accumulation ratio) by LC-MS/MS after single and 14-day oral BIO101; plasma myostatin by ELISA, change from baseline at day 14 against pooled placebo
increases, small dose-dependent increase in mean myostatin after 14 days of BIO101 against a decrease on placebo, p = 0.032
Not recorded as a finding: this platform holds no node for the endpoint
Mean myostatin levels tended to decrease compared with baseline in subjects who received placebo, while a small increase was observed after 14 days of repeated administration of BIO101, in a dose-dependent manner (Kruskal–Wallis test P = 0.032).
PMID 37057316 · one of two readings recorded this
renin, change from baseline at D14
no effect, p = 0.103
Renin (pg/mL) | 0.405 (−1.11 + 2.14) | −0.554 (−5.82 + 1.39) | 1.064 (n = 7) (−0.33 + 4.25) | −1.131 (−6.02 + 4.20) | 0.103 (ns) | All: 0.669 (ns) 350 mg bid: 0.584 | 0.01 0.06
PMID 37057316 · one of two readings recorded this
All-cause mortality at day 28, adjusted difference (CMH)
no effect, n = 233
adjusted difference: −6.2%, 95% CI: [−14.5%, 2.2%]
PMID 38545090 · one of two readings recorded this
All-cause mortality at day 28, observed proportion
decreases
The proportions of subjects with death from any cause at Day 28 (7.9% vs. 14% in the BIO101 vs. placebo arms respectively)
PMID 38545090 · one of two readings recorded this
All negative events by day 28, sensitivity analysis logistic regression
decreases
odds ratio (OR) of 0.47 (95% CI: 0.23, 0.95)
PMID 38545090 · one of two readings recorded this
composite of death or respiratory failure requiring mechanical ventilation, ECMO or high-flow oxygen by day 28, first negative event, CMH test (primary endpoint)
decreases, adjusted difference -11.4% (95% CI -22.4%, -0.4%), p = 0.0426
Not recorded as a finding: no_outcome_node: no node for a composite of death or respiratory failure; the closest nodes (all-cause mortality, mechanical-ventilation-duration) measure different constructs.
In the mITT population, using the CMH test with multiple imputation for missing data, the first negative event rate was statistically significantly lower in the BIO101 group than in the placebo group (adjusted difference: −11.4% [95% CI: −22.4%, −0.4%]; p = 0.0426) (Table 2 A).
PMID 38545090 · one of two readings recorded this
Death or respiratory failure at or before day 28, observed proportion
decreases, n = 233
The observed proportion of subjects who met the primary outcome of death or respiratory failure at or before day 28, were 13.5% vs. 24.3%
PMID 38545090 · one of two readings recorded this
Death or respiratory failure by day 28 (first negative event), adjusted difference, CMH with multiple imputation
decreases, p = 0.0426, n = 233
adjusted difference: −11.4% [95% CI: −22.4%, −0.4%]; p = 0.0426
PMID 38545090 · one of two readings recorded this
Difference in proportions of deaths at 90 days
no effect
The difference in the proportions of deaths at 90 days was 0.093 (95% confidence interval (−0.010, 0.195))
PMID 38545090 · one of two readings recorded this
Discharged from hospital due to improvement at day 28 (key secondary), adjusted difference
no effect, p = 0.0568, n = 233
adjusted difference: 11.0% [95% CI: −0.4%, 22.4%], p = 0.0568
PMID 38545090 · one of two readings recorded this
Discharged from hospital due to improvement at day 28, observed proportion
increases
The proportion of subjects discharged from hospital due to improvement (positive events) at day 28 was numerically higher in the BIO101 group (80.1%) than in the placebo group (70.9%)
PMID 38545090 · one of two readings recorded this
First negative event: death from any cause
decreases
Death from any cause | 1 (0.8) | 3 (2.8)
PMID 38545090 · one of two readings recorded this
First negative event: respiratory failure requiring ECMO
no effect
Requiring ECMO | 0 | 0
PMID 38545090 · one of two readings recorded this
First negative event: respiratory failure requiring high flow oxygen
decreases
Requiring high flow oxygen d | 2 (1.6) | 8 (7.5)
PMID 38545090 · one of two readings recorded this
First negative event: respiratory failure requiring mechanical ventilation
decreases
Requiring mechanical ventilation | 14 (11.1) | 15 (14.0)
PMID 38545090 · one of two readings recorded this
First negative event: respiratory failure
decreases
Respiratory failure | 16 (12.7) | 23 (21.5)
PMID 38545090 · one of two readings recorded this
hospital discharge due to improvement by day 28 (key secondary endpoint)
no effect, 80.1% vs 70.9%, adjusted difference 11.0% (95% CI -0.4%, 22.4%)
Not recorded as a finding: no_outcome_node: no node for proportion discharged following recovery.
The proportion of subjects discharged from hospital due to improvement (positive events) at day 28 was numerically higher in the BIO101 group (80.1%) than in the placebo group (70.9%) although this difference did not reach statistical significance (adjusted difference: 11.0% [95% CI: −0.4%, 22.4%], p = 0.0568) (Table 2 A).
PMID 38545090 · one of two readings recorded this
Key secondary endpoint, first positive events (table)
no effect, p = 0.0586
Key secondary endpoint b Proportion of patients discharged from hospital due to improvement. (First positive events) | 100.94 (80.1) | 75.91 (70.9) | 9.2 | 11.0 (−0.4, 22.4) | 0.0586
PMID 38545090 · one of two readings recorded this
Mean number of days on treatment
no effect
the mean number of days on treatment (BIO101; 8.9 ± 6.13 days vs. Placebo; 7.6 ± 5.36 days)
PMID 38545090 · one of two readings recorded this
Mortality at day 28 death from any cause (table)
no effect, p = 0.1476
Mortality at day 28 c Death from any cause | 10 (7.9) | 15 (14.0) | −6.1 | −6.2 (−14.5, 2.2) | 0.1476 (nominal)
PMID 38545090 · one of two readings recorded this
Negative events at day 28, sensitivity analysis Kaplan-Meier proportions difference
decreases
difference 10.9%, 95% CI [0.6%, 21.2%]
PMID 38545090 · one of two readings recorded this
Number of subjects with first negative event
decreases
Number of subjects with first negative event | 17 (13.5) | 26 (24.3)
PMID 38545090 · one of two readings recorded this
Number of subjects with positive event (discharge)
unclear
Number of subjects with positive event e | 93 (73.8) | 71 (66.4)
PMID 38545090 · one of two readings recorded this
Primary endpoint adjusted difference, Brazil
no effect
adjusted difference: −12.1%, 95% CI [−25.7%, 1.6%]
PMID 38545090 · one of two readings recorded this
Primary endpoint adjusted difference, France, Belgium and US
no effect
adjusted difference −0.14%, 95% CI [−23.3%, 23.0%]
PMID 38545090 · one of two readings recorded this
Primary endpoint adjusted difference, protocol versions 1 to 11
decreases
protocol versions 1 to 11 adjusted difference −7.08%, 95% CI [−21.1%, 6.91%]
PMID 38545090 · one of two readings recorded this
Primary endpoint adjusted difference, protocol versions 12-13
decreases
protocols 12-13 adjusted difference: −16.2%, 95% CI [−33.6%, 1.22%]
PMID 38545090 · one of two readings recorded this
Primary endpoint first negative events (table), unadjusted and adjusted difference
decreases, p = 0.0426
Proportion of patients with death or respiratory failure (First negative events) Primary endpoint d | 19.85 (15.8) | 27.86 (26.0) | −10.3 | −11.4 (−22.4, −0.4) | 0.0426
PMID 38545090 · one of two readings recorded this
proportion of patients with any treatment-emergent adverse event, on-intervention period
decreases, 73 [57.0%] vs 67 [64.4%]
Not recorded as a finding: Node supplement-adverse-event-incidence fits, but the sentence gives a direction word and counts with no test or interval, so neither direction is recordable.
A lower proportion of patients treated with BIO101 experienced any type of TEAEs than placebo subjects (73 [57.0%] vs. 67 [64.4%], respectively).
PMID 38545090 · one of two readings recorded this
Relative risk reduction of death at day 28
decreases
BIO101 had a RR reduction of death of 44.3% compared to placebo
PMID 38545090 · one of two readings recorded this
Relative risk reduction of negative events
decreases
The RR of having negative events was reduced by 43.8% in the BIO101 arm
PMID 38545090 · one of two readings recorded this
Respiratory failure as first negative event
decreases
The most common negative event was respiratory failure and was numerically reduced in the BIO101 group compared to the placebo group (16 subjects, 12.7% vs. 23 subjects, 21.5% respectively)
PMID 38545090 · one of two readings recorded this
Time to death through day 90, hazard ratio (Cox model)
no effect
The hazard ratio for time to death through day 90 was 0.554 (95% CI: 0.285, 1.077)
PMID 38545090 · one of two readings recorded this
Time to negative event, Kaplan-Meier hazard ratio
decreases, p = 0.0223
Hazard Ratio (95% CI): 0.489 (0.265, 0.904)/Two-sided p-value Log-rank p = 0.0223
PMID 38545090 · one of two readings recorded this
Time to respiratory failure through day 90, hazard ratio (Kaplan Meier)
no effect
Kaplan Meier comparison of the time to respiratory failure at Day 90 between the BIO101 and the placebo groups did not reach statistical significance either (HR: 0.530 (95% CI: 0.279, 1.006)
PMID 38545090 · one of two readings recorded this
4-m walk gait speed from SPPB, LS mean difference to placebo in CFB at Month 6
no effect, p = 0.8747
The LS mean (SE) difference to placebo at Month 6 in the GS from the 4‐m walk test from SPPB in the PP population was 0.011 (0.067) and 0.134 (0.074) m/s in the 175‐ and 350‐mg BIO101groups, respectively (p = 0.8747 and p = 0.0745, respectively)
PMID 40026058 · one of two readings recorded this
4-m walk gait speed from SPPB, LS mean difference to placebo in CFB at Month 6
no effect, p = 0.0745
The LS mean (SE) difference to placebo at Month 6 in the GS from the 4‐m walk test from SPPB in the PP population was 0.011 (0.067) and 0.134 (0.074) m/s in the 175‐ and 350‐mg BIO101groups, respectively (p = 0.8747 and p = 0.0745, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed difference vs placebo at M6, p-value (table)
no effect, p = 0.2338
p‐value | 0.2338 | 0.0966 | 0.6355 | 0.0492
PMID 40026058 · one of two readings recorded this
400MWT gait speed difference vs placebo at M6, p-value (table)
no effect, p = 0.8236
p‐value | 0.8236 | 0.2878 | 0.4706 | 0.1395
PMID 40026058 · one of two readings recorded this
400MWT gait speed difference vs placebo at M6, p-value (table)
no effect, p = 0.7592
p‐value | 0.7592 | 0.1415 | 0.1278 | 0.1268
PMID 40026058 · one of two readings recorded this
400MWT gait speed difference vs placebo at M6, p-value (table)
no effect, p = 0.0966
p‐value | 0.2338 | 0.0966 | 0.6355 | 0.0492
PMID 40026058 · one of two readings recorded this
400MWT gait speed difference vs placebo at M6, p-value (table)
no effect, p = 0.2878
p‐value | 0.8236 | 0.2878 | 0.4706 | 0.1395
PMID 40026058 · one of two readings recorded this
400MWT gait speed difference vs placebo at M6, p-value (table)
no effect, p = 0.1415
p‐value | 0.7592 | 0.1415 | 0.1278 | 0.1268
PMID 40026058 · one of two readings recorded this
400MWT gait speed LS mean CFB at M6
LS mean CFB M6 (SE), m/s | 0.0018 (0.02903) | 0.0523 (0.03325) | 0.0680 (0.02939) | 0.0139 (0.03104) | −0.0114 (0.04451) | 0.1035 (0.03297)
PMID 40026058 · one of two readings recorded this
400MWT gait speed LS mean CFB at M6
LS mean CFB M6 (SE), m/s | 0.0220 (0.03341) | 0.0326 (0.03626) | 0.0694 (0.03215) | 0.0279 (0.03415) | ‐0.0125 (0.04532) | 0.1024 (0.03677)
PMID 40026058 · one of two readings recorded this
400MWT gait speed LS mean CFB at M6
LS mean CFB M6 (SE), m/s | 0.0203 (0.02677) | 0.0318 (0.02854) | 0.0724 (0.02485) | 0.0319 (0.02662) | −0.0359 (0.03601) | 0.0888 (0.02753)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference to placebo in CFB to Month 6, new analysis with MI
no effect, p = 0.692
The LS mean (SE) difference to placebo in CFB to Month 6 was 0.012 (0.031) m/s and 0.069 (0.040) m/s in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.6920 and p = 0.0850, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference to placebo in CFB to Month 6, new analysis with MI
no effect, p = 0.085
The LS mean (SE) difference to placebo in CFB to Month 6 was 0.012 (0.031) m/s and 0.069 (0.040) m/s in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.6920 and p = 0.0850, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference to placebo in change from baseline, primary analysis
no effect, p = 0.2437
the least square (LS) mean (SE) difference to placebo in change from baseline to Month 6/9 was 0.036 (0.031) m/s and 0.039 (0.030) m/s in the 175‐and 350‐mg BIO101 groups, respectively (p = 0.2437 and p = 0.2000, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference to placebo in change from baseline, primary analysis
no effect, p = 0.2
the least square (LS) mean (SE) difference to placebo in change from baseline to Month 6/9 was 0.036 (0.031) m/s and 0.039 (0.030) m/s in the 175‐and 350‐mg BIO101 groups, respectively (p = 0.2437 and p = 0.2000, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed LS mean difference vs placebo at M6 (table)
LS mean difference (vs placebo)(SE) | 0.0505 (0.04209) | 0.0662 (0.03938) | −0.0254 (0.05318) | 0.0895 (0.04429)
PMID 40026058 · one of two readings recorded this
400MWT gait speed LS mean difference vs placebo at M6 (table)
LS mean difference (vs placebo)(SE) | 0.0105 (0.04709) | 0.0474 (0.04417) | ‐0.0404 (0.05550) | 0.0745 (0.04940)
PMID 40026058 · one of two readings recorded this
400MWT gait speed LS mean difference vs placebo at M6 (table)
LS mean difference (vs placebo) (SE) | 0.0115 (0.03722) | 0.0521 (0.03505) | −0.0678 (0.04382) | 0.0569 (0.03658)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference vs placebo in CFB to Month 6
no effect, p = 0.6355
the LS mean (SE) difference compared with placebo in CFB to Month 6 was −0.025 (0.053) m/s and 0.090 (0.044) m/s in the 175‐ and 350‐mg BIO101 groups, respectively, statistically nominally significant for the latter (p = 0.6355 and p = 0.0492, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference vs placebo in CFB to Month 6
no effect, p = 0.4706
the LS mean (SE) difference versus placebo in CFB to Month 6 was −0.040 (0.056) m/s and 0.075 (0.049) m/s in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.4706 and p = 0.1395, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference vs placebo in CFB to Month 6
no effect, p = 0.1278
the LS mean (SE) difference versus placebo in CFB to Month 6 was −0.068 (0.044) m/s and 0.057 (0.037) m/s in the 175‐ and 350‐mg BIO101groups, respectively (p = 0.1278 and p = 0.1268, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference vs placebo in CFB to Month 6
increases, p = 0.0492
the LS mean (SE) difference compared with placebo in CFB to Month 6 was −0.025 (0.053) m/s and 0.090 (0.044) m/s in the 175‐ and 350‐mg BIO101 groups, respectively, statistically nominally significant for the latter (p = 0.6355 and p = 0.0492, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference vs placebo in CFB to Month 6
no effect, p = 0.1395
the LS mean (SE) difference versus placebo in CFB to Month 6 was −0.040 (0.056) m/s and 0.075 (0.049) m/s in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.4706 and p = 0.1395, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, LS mean difference vs placebo in CFB to Month 6
no effect, p = 0.1268
the LS mean (SE) difference versus placebo in CFB to Month 6 was −0.068 (0.044) m/s and 0.057 (0.037) m/s in the 175‐ and 350‐mg BIO101groups, respectively (p = 0.1278 and p = 0.1268, respectively)
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed change from baseline at 6 months
decreases
with the change from baseline being −0.023 (0.128) m/s
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed difference between arm and placebo
unclear
The observed difference between treatment arms and placebo was 0.045 and 0.066 m/s for 175 and 350 mg BIO101, respectively, at M6/M9
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed difference between arm and placebo
unclear
At M6, the observed difference between treatment arms and placebo was 0.037 and 0.086 m/s for the 175‐ and 350‐mg BIO101 groups, respectively
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed difference between arm and placebo
unclear
0.019 and 0.078 m/s for 175 and 350 mg BIO101, respectively, at M6/M9
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed difference between arm and placebo
unclear
In the PP population, the observed difference between treatment arms and placebo was −0.019 and 0.102 m/s for 175 and 350 mg BIO101, respectively, at M6
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed difference between arm and placebo
unclear
The observed difference between treatment arms and placebo was 0.045 and 0.066 m/s for 175 and 350 mg BIO101, respectively, at M6/M9
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed difference between arm and placebo
unclear
At M6, the observed difference between treatment arms and placebo was 0.037 and 0.086 m/s for the 175‐ and 350‐mg BIO101 groups, respectively
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed difference between arm and placebo
unclear
0.019 and 0.078 m/s for 175 and 350 mg BIO101, respectively, at M6/M9
PMID 40026058 · one of two readings recorded this
400MWT gait speed, observed difference between arm and placebo
unclear
In the PP population, the observed difference between treatment arms and placebo was −0.019 and 0.102 m/s for 175 and 350 mg BIO101, respectively, at M6
PMID 40026058 · one of two readings recorded this
400MWT test response, adjusted odds ratio vs placebo
no effect
Adjusted OR (95% CI) (vs placebo) [a] | 2.57 (0.75–8.82) | 3.15 (0.95–10.43)
PMID 40026058 · one of two readings recorded this
400MWT test response, adjusted odds ratio vs placebo
no effect
Adjusted OR (95% CI) (vs placebo) [a] | 2.57 (0.75–8.82) | 3.15 (0.95–10.43)
PMID 40026058 · one of two readings recorded this
400MWT test response, number of responders at M6/M9
Number of responders with M6/M9 | 4 | 9 | 11
PMID 40026058 · one of two readings recorded this
400MWT test response, p-value for adjusted OR
no effect, p = 0.1321
p‐value [a] | 0.1321 | 0.0603
PMID 40026058 · one of two readings recorded this
400MWT test response, p-value for adjusted OR
no effect, p = 0.0603
p‐value [a] | 0.1321 | 0.0603
PMID 40026058 · one of two readings recorded this
6-min walking distance, LS mean difference to placebo at Month 6/9
no effect, p = 0.8824
the LS mean (SE) difference to placebo at Month 6/9 in the distance walked during the 6‐min walking distance (6MWD) test was 2.714 m (18.300) and 25.607 m (17.982) in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.8824 and p = 0.1578, respectively)
PMID 40026058 · one of two readings recorded this
6-min walking distance, LS mean difference to placebo at Month 6/9
no effect, p = 0.1578
the LS mean (SE) difference to placebo at Month 6/9 in the distance walked during the 6‐min walking distance (6MWD) test was 2.714 m (18.300) and 25.607 m (17.982) in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.8824 and p = 0.1578, respectively)
PMID 40026058 · one of two readings recorded this
6MWD, LS mean CFB M6/9
LS mean CFB M6/9 (SE) | −9.879 (13.6981) | −7.166 (14.7976) | 15.728 (13.4459)
PMID 40026058 · one of two readings recorded this
ALM/BMI calculated, LS mean CFB M6/9
LS mean CFB M6/9 (SE) | −0.001 (0.0101) | −0.010 (0.0112) | 0.007 (0.0097)
PMID 40026058 · one of two readings recorded this
ALM/BMI calculated, LS mean difference vs placebo M6/9, p-value
no effect, p = 0.4721
p‐value | 0.4721 | 0.5554
PMID 40026058 · one of two readings recorded this
ALM/BMI calculated, LS mean difference vs placebo M6/9, p-value
no effect, p = 0.5554
p‐value | 0.4721 | 0.5554
PMID 40026058 · one of two readings recorded this
ALM/BMI calculated, LS mean difference vs placebo M6/9
no effect
LS mean difference vs Placebo (SE) | −0.009 (0.0131) | 0.008 (0.0130)
PMID 40026058 · one of two readings recorded this
ALM, LS mean CFB M6/9
LS mean CFB M6/9 (SE) | −0.276 (0.3176) | −0.283 (0.3307) | 0.068 (0.2822)
PMID 40026058 · one of two readings recorded this
ALM, LS mean difference vs placebo M6/9, p-value
no effect, p = 0.9859
p‐value | 0.9859 | 0.4040
PMID 40026058 · one of two readings recorded this
ALM, LS mean difference vs placebo M6/9, p-value
no effect, p = 0.404
p‐value | 0.9859 | 0.4040
PMID 40026058 · one of two readings recorded this
ALM, LS mean difference vs placebo M6/9
no effect
LS mean difference vs placebo (SE) | −0.007 (0.3859) | 0.344 (0.4096)
PMID 40026058 · one of two readings recorded this
gait speed change from baseline on the 400-m walking test (400MWT), primary endpoint
LS mean difference to placebo 0.036 (0.031) m/s and 0.039 (0.030) m/s in the 175 and 350 mg BIO101 groups
Not recorded as a finding: this platform holds no node for the endpoint
In the primary analysis of 400MWT GS in the FAS, the least square (LS) mean (SE) difference to placebo in change from baseline to Month 6/9 was 0.036 (0.031) m/s and 0.039 (0.030) m/s in the 175‐and 350‐mg BIO101 groups, respectively (p = 0.2437 and p = 0.2000, respectively).
PMID 40026058 · one of two readings recorded this
Handgrip strength dominant hand, LS mean CFB M6/9
LS mean CFB M6/9 (SE) | −0.709 (1.1024) | −1.601 (1.1731) | 0.590 (1.0668)
PMID 40026058 · one of two readings recorded this
Handgrip strength dominant hand, LS mean difference from placebo in CFB to Month 6/9
no effect, p = 0.52
the LS mean (SE) difference from placebo in CFB to Month 6/9 was −0.892 (1.381) and 1.298 (1.404) in the 175‐mg and 350‐mg BIO101 groups, respectively, which was not statistically significant (p = 0.5200 and p = 0.3577, respectively)
PMID 40026058 · one of two readings recorded this
Handgrip strength dominant hand, LS mean difference from placebo in CFB to Month 6/9
no effect, p = 0.3577
the LS mean (SE) difference from placebo in CFB to Month 6/9 was −0.892 (1.381) and 1.298 (1.404) in the 175‐mg and 350‐mg BIO101 groups, respectively, which was not statistically significant (p = 0.5200 and p = 0.3577, respectively)
PMID 40026058 · one of two readings recorded this
MMRM treatment factor significance, 400MWT gait speed CFB M6, chair stand and obesity analysis
increases, p = 0.0037
treatment was a significant factor in the MMRM analysis (p = 0.0037)
PMID 40026058 · one of two readings recorded this
MMRM treatment factor significance, 400MWT gait speed CFB M6, low gait speed analysis
increases, p = 0.0154
treatment was a significant factor in the MMRM analysis (p = 0.0154)
PMID 40026058 · one of two readings recorded this
PF-10 from SF-36, LS mean CFB M6/9
LS mean CFB M6/9 (SE) | 7.3 (2.50) | 7.1 (2.64) | 7.1 (2.51)
PMID 40026058 · one of two readings recorded this
PF-10 sub-score of SF-36, LS mean difference to placebo in CFB to Month 6/9
no effect, p = 0.9408
the LS mean (SE) difference to placebo in CFB to Month 6/9 was −0.2 (3.30) and −0.2 (3.25) in the 175‐ and 350‐mg BIO101 groups, respectively, which was not statistically significant (p = 0.9408 and p = 0.9485, respectively)
PMID 40026058 · one of two readings recorded this
PF-10 sub-score of SF-36, LS mean difference to placebo in CFB to Month 6/9
no effect, p = 0.9485
the LS mean (SE) difference to placebo in CFB to Month 6/9 was −0.2 (3.30) and −0.2 (3.25) in the 175‐ and 350‐mg BIO101 groups, respectively, which was not statistically significant (p = 0.9408 and p = 0.9485, respectively)
PMID 40026058 · one of two readings recorded this
SarQoL, LS mean CFB M6/9
LS mean CFB M6/9 (SE) | 14.66 (2.017) | 10.81 (2.074) | 10.00 (1.979)
PMID 40026058 · one of two readings recorded this
SarQoL, LS mean difference vs placebo M6/9, p-value
no effect, p = 0.1348
p‐value | 0.1348 | 0.0666
PMID 40026058 · one of two readings recorded this
SarQoL, LS mean difference vs placebo M6/9, p-value
no effect, p = 0.0666
p‐value | 0.1348 | 0.0666
PMID 40026058 · one of two readings recorded this
SarQoL, LS mean difference vs placebo M6/9
no effect
LS mean difference vs placebo (SE) | −3.85 (2.559) | −4.67 (2.521)
PMID 40026058 · one of two readings recorded this
SPPB total score, LS mean CFB M6/9
LS mean CFB M6/9 (SE) | 1.1 (0.35) | 1.0 (0.35) | 0.9 (0.33)
PMID 40026058 · one of two readings recorded this
SPPB total score, LS mean difference vs placebo M6/9, p-value
no effect, p = 0.8127
p‐value | 0.8127 | 0.6663
PMID 40026058 · one of two readings recorded this
SPPB total score, LS mean difference vs placebo M6/9, p-value
no effect, p = 0.6663
p‐value | 0.8127 | 0.6663
PMID 40026058 · one of two readings recorded this
SPPB total score, LS mean difference vs placebo M6/9
no effect
LS mean difference vs placebo (SE) | −0.1 (0.47) | −0.2 (0.46)
PMID 40026058 · one of two readings recorded this
abdominal fat, change
decreases, p = 0.05
The 20E group showed significant reductions in arm (p<0.01), leg (p<0.05), and abdominal fat (p<0.05), with arm fat reduction significantly greater than in the PLA group (p<0.05)
PMID 41485968 · one of two readings recorded this
arm fat, change
decreases, p = 0.01
The 20E group showed significant reductions in arm (p<0.01), leg (p<0.05), and abdominal fat (p<0.05), with arm fat reduction significantly greater than in the PLA group (p<0.05)
PMID 41485968 · one of two readings recorded this
arm fat reduction, 20E versus PLA
decreases, p = 0.05
The 20E group showed significant reductions in arm (p<0.01), leg (p<0.05), and abdominal fat (p<0.05), with arm fat reduction significantly greater than in the PLA group (p<0.05)
PMID 41485968 · one of two readings recorded this
fasting insulin, change
decreases, p = 0.01
favorable metabolic changes, including reductions in fasting insulin (p<0.01) and plasma FFAs (p<0.05), alongside an increase in QUICKI (p<0.01)
PMID 41485968 · one of two readings recorded this
fasting insulin, plasma free fatty acids and QUICKI; substrate (fat) oxidation at rest and during exercise; arm, leg and abdominal fat; abstract only, 30 mg/d 20E from Asparagus officinalis extract vs placebo, 12 wk with resistance training
decreases, fasting insulin reduced (p<0.01), plasma FFAs reduced (p<0.05), QUICKI increased (p<0.01), reported for the 20E group without a stated between-group contrast
Not recorded as a finding: the result compares a group with itself, not with a control
Furthermore, 20E supplementation was associated with favorable metabolic changes, including reductions in fasting insulin (p<0.01) and plasma FFAs (p<0.05), alongside an increase in QUICKI (p<0.01).
PMID 41485968 · one of two readings recorded this
fat oxidation, 20E versus PLA
increases, p = 0.05
Fat oxidation increased at rest and during exercise in the 20E group (p<0.01), with between-group differences evident only at 40% of V•O2peak (p<0.05)
PMID 41485968 · one of two readings recorded this
fat oxidation at rest and during exercise, change
increases, p = 0.01
Fat oxidation increased at rest and during exercise in the 20E group (p<0.01), with between-group differences evident only at 40% of V•O2peak (p<0.05)
PMID 41485968 · one of two readings recorded this
leg fat, change
decreases, p = 0.05
The 20E group showed significant reductions in arm (p<0.01), leg (p<0.05), and abdominal fat (p<0.05), with arm fat reduction significantly greater than in the PLA group (p<0.05)
PMID 41485968 · one of two readings recorded this
plasma free fatty acids, change
decreases, p = 0.05
favorable metabolic changes, including reductions in fasting insulin (p<0.01) and plasma FFAs (p<0.05), alongside an increase in QUICKI (p<0.01)
PMID 41485968 · one of two readings recorded this
QUICKI, change
increases, p = 0.01
favorable metabolic changes, including reductions in fasting insulin (p<0.01) and plasma FFAs (p<0.05), alongside an increase in QUICKI (p<0.01)
PMID 41485968 · one of two readings recorded this
whole-body fat oxidation at rest and during exercise (substrate utilization); fasting insulin and plasma free fatty acids; QUICKI; regional (arm, leg, abdominal) fat. Abstract only. The 20E-group changes are within-arm, and the only between-group result stated is at 40% of VO2peak or for arm fat, which are subsets or a regional measure the nodes do not cover
increases, fat oxidation increased at rest and during exercise in the 20E group; between-group difference only at 40% of VO2peak
Not recorded as a finding: the result compares a group with itself, not with a control
Fat oxidation increased at rest and during exercise in the 20E group (p<0.01), with between-group differences evident only at 40% of V•O2peak (p<0.05).
PMID 41485968 · one of two readings recorded this